# BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Source: https://onco.cc/trials/nct05120271/  
OnCo record `nct05120271` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CAR-GPC3 T Cells in hepatocellular carcinoma, non-small-cell lung cancer, merkel cell carcinoma and sarcomas, run by Sotio Biotech Inc., active and no longer recruiting.

## Summary

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors is a phase 1/2 interventional study registered as NCT05120271 by Sotio Biotech Inc., with 7 participants enrolled, started 2022-10-26 and due to reach its primary completion in 2025-10-24. Interventions recorded: CAR-GPC3 T Cells.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05120271
- Phase: 1/2
- Setting: A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
- Sponsor: Sotio Biotech Inc.
- Enrolled: 7

## Sources

- ClinicalTrials.gov NCT05120271: https://clinicaltrials.gov/study/NCT05120271

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [SOTIO Biotech](https://onco.cc/companies/sotio/)

---
JSON: https://onco.cc/api/v1/entities/nct05120271.json